SPARCL1 and cutaneous melanoma: We next integrated the GTEx database and TCGA database and assessed the SPARCL1 transcriptional level in 11 other cancers, including adrenocortical carcinoma (ACC), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), acute myeloid leukemia (LAML), brain lower-grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), sarcoma (SARC), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), thymoma (THYM), uterine carcinosarcoma (UCS), and uveal melanoma (UVM).